Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Camila Masias, MDMPH, Rawan Tarawneh, MD, Haiwa Wu, Krista Carter, Shangbin Yang, PhD, Alcinda Flowers, MD, Marie Scully, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 2377.

https://doi.org/10.1182/blood-2019-130369

Published: 2019

Journal Articles

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Deirdra Terrell, PhD, Spero Cataland, MD, Laura Beebe, PhD, San Keller, PhD MS, Julie Panepinto, MDMSPH, Sara K. Vesely, PhD MPH, James George, MD, Rachel Ann Kelley, BS, Marshall Cheney, PhD

Blood (2019) 134 (Supplement_1): 931.

https://doi.org/10.1182/blood-2019-128989

Published: 2019

Journal Articles

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Blood (2019) 134 (Supplement_1): 90.

https://doi.org/10.1182/blood-2019-129383

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Blood (2019) 134 (Supplement_1): 1066.

https://doi.org/10.1182/blood-2019-131064

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Camila Masias, MDMPH, Krista Carter, Haiwa Wu, Shangbin Yang, PhD, Alcinda Flowers, MD, Spero Cataland, MD

Blood (2019) 134 (Supplement_1): 1098.

https://doi.org/10.1182/blood-2019-130561

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Post Traumatic Stress Disorder and Depression in Survivors of Thrombotic Thrombocytopenic Purpura

Shruti Chaturvedi, MBBS, Olalekan O Oluwole, MBBS, MPH, Sydney Kodatsky, Spero Cataland, MD, Keith R. McCrae, MD

Blood (2016) 128 (22): 1364.

https://doi.org/10.1182/blood.V128.22.1364.1364

Published: 2016

Journal Articles

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Kurt P. Leuenberger, MD, Spero Cataland, MD, Ming Jin, MD, PhD, Carol Orr, Guido Marcucci, MD, Eric H. Kraut, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 2150.

https://doi.org/10.1182/blood.V106.11.2150.2150

Published: 2005

Journal Articles

A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry.

Haifeng Wu, MD, Spero Cataland, MD, Michael Bissell, MD, PhD, Ming Jin, MD, PhD

Blood (2005) 106 (11): 2660.

https://doi.org/10.1182/blood.V106.11.2660.2660

Published: 2005

Journal Articles

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Wendy Stock, MD, Daohai Yu, PhD, Ben Sanford, MS, Gerard Lozanski, Ph.D, Spero Cataland, MD, Ravi Vij, MD, John Byrd, MD, Bayard Powell, MD, Meir Wetzler, MD, Maher Albitar, MD, Dorie Sher, BS, Colin Edwards, MS, Eva Hoke, BS, Clara D. Bloomfield, MD, Richard A. Larson, MD

Blood (2005) 106 (11): 145.

https://doi.org/10.1182/blood.V106.11.145.145

Published: 2005

NARROW

A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Post Traumatic Stress Disorder and Depression in Survivors of Thrombotic Thrombocytopenic Purpura

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry.

Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only